Published in Int J Cancer on October 11, 2012
Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults. Am J Epidemiol (2014) 1.88
Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomarkers Prev (2013) 1.42
Up-regulation of FOXM1 by E6 oncoprotein through the MZF1/NKX2-1 axis is required for human papillomavirus-associated tumorigenesis. Neoplasia (2014) 0.89
Long-term persistence of oral human papillomavirus type 16: the HPV Infection in Men (HIM) study. Cancer Prev Res (Phila) (2015) 0.89
Key considerations and current perspectives of epidemiological studies on human papillomavirus persistence, the intermediate phenotype to cervical cancer. Int J Infect Dis (2013) 0.86
Human papillomavirus genomics: past, present and future. Curr Probl Dermatol (2014) 0.85
The Interaction between Human Immunodeficiency Virus and Human Papillomaviruses in Heterosexuals in Africa. J Clin Med (2015) 0.85
A prospective study of age trends of high-risk human papillomavirus infection in rural China. BMC Infect Dis (2014) 0.83
Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial. BMC Cancer (2015) 0.82
Discrete-time semi-Markov modeling of human papillomavirus persistence. Stat Med (2011) 0.81
DAPK1 Promoter Methylation and Cervical Cancer Risk: A Systematic Review and a Meta-Analysis. PLoS One (2015) 0.79
The Role of Chlamydia trachomatis in High-Risk Human Papillomavirus Persistence Among Female Sex Workers in Nairobi, Kenya. Sex Transm Dis (2015) 0.78
Human papillomavirus-exposed Langerhans cells are activated by stabilized Poly-I:C. Papillomavirus Res (2015) 0.78
Variants in interleukin family of cytokines genes influence clearance of high risk HPV in HIV-1 coinfected African-American adolescents. Hum Immunol (2013) 0.78
Tumour suppressor gene methylation and cervical cell folate concentration are determinants of high-risk human papillomavirus persistence: a nested case control study. BMC Cancer (2014) 0.78
Persistent infection with human papillomavirus 16 or 18 is strongly linked with high-grade cervical disease. Hum Vaccin Immunother (2016) 0.77
Candidate Soluble Immune Mediators in Young Women with High-Risk Human Papillomavirus Infection: High Expression of Chemokines Promoting Angiogenesis and Cell Proliferation. PLoS One (2016) 0.77
The association between adverse pregnancy outcomes and maternal human papillomavirus infection: a systematic review protocol. Syst Rev (2017) 0.75
Metabolic Syndrome and Risk of Cervical Human Papillomavirus Incident and Persistent Infection. Medicine (Baltimore) (2016) 0.75
Bonafide, type-specific human papillomavirus persistence among HIV-positive pregnant women: predictive value for cytological abnormalities, a longitudinal cohort study. Mem Inst Oswaldo Cruz (2016) 0.75
Incidence and persistence of carcinogenic genital human papillomavirus infections in young women with or without Chlamydia trachomatis co-infection. Cancer Med (2015) 0.75
Human Papillomavirus (HPV) virion induced cancer and subfertility, two sides of the same coin. Facts Views Vis Obgyn (2017) 0.75
p16/Ki-67 co-expression associates high risk human papillomavirus persistence and cervical histopathology: a 3-year cohort study in China. Oncotarget (2016) 0.75
Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): A systematic review. Int J Cancer (2017) 0.75
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
The causal relation between human papillomavirus and cervical cancer. J Clin Pathol (2002) 14.73
Classification of papillomaviruses. Virology (2004) 14.16
Human papillomavirus and cervical cancer. Lancet (2007) 12.47
Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med (1998) 11.61
Improved amplification of genital human papillomaviruses. J Clin Microbiol (2000) 11.50
Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer (2007) 10.29
Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med (2007) 9.53
Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med (1999) 9.40
Detecting and describing heterogeneity in meta-analysis. Stat Med (1998) 8.44
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 8.09
Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet (2001) 7.31
Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis (1994) 7.00
What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med (2004) 5.67
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med (2007) 5.57
Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet (2003) 5.39
The carcinogenicity of human papillomavirus types reflects viral evolution. Virology (2005) 4.72
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2006) 4.33
Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med (1997) 4.00
A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis (2005) 3.46
Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev (2005) 3.40
Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis (1999) 3.35
Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst (2008) 3.32
Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA (2001) 3.07
Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst (1999) 2.98
Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol (2008) 2.91
Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med (1999) 2.79
Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis (2004) 2.77
Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ (2009) 2.68
Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol (2000) 2.63
Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer (2003) 2.53
The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev (2003) 2.52
Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis (2001) 2.51
Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis (2005) 2.51
Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer (2001) 2.26
A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis (2000) 2.24
The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res (2006) 2.08
Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ (2003) 2.04
Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis (2001) 1.99
Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol (2003) 1.96
Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis (1995) 1.94
Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. J Infect Dis (2002) 1.77
Regional distribution and incidence of human papillomavirus infections among heterosexual men and women with multiple sexual partners: a prospective study. Genitourin Med (1994) 1.73
Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. Cancer Res (2008) 1.73
Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J Infect Dis (2008) 1.72
Human papillomavirus type specific DNA and RNA persistence--implications for cervical disease progression and monitoring. J Med Virol (2004) 1.69
Comparison of the SPF10-LiPA system to the Hybrid Capture 2 Assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica. J Clin Microbiol (2007) 1.64
Comparison of two PCR-based human papillomavirus genotyping methods. J Clin Microbiol (2008) 1.59
Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women. Cancer Res (2006) 1.59
Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women. Am J Epidemiol (2000) 1.57
Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet (2001) 1.56
High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. Int J Cancer (2007) 1.47
Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer (2005) 1.39
Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women. Br J Cancer (2009) 1.37
Invited commentary: is monitoring of human papillomavirus infection for viral persistence ready for use in cervical cancer screening? Am J Epidemiol (2008) 1.35
Biases in human papillomavirus genotype prevalence assessment associated with commonly used consensus primers. Int J Cancer (2006) 1.33
Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer (2004) 1.33
Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. Int J Cancer (2010) 1.32
Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression. Virology (2011) 1.30
Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study. J Clin Pathol (2005) 1.29
Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. Int J Cancer (2007) 1.27
High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer (2007) 1.24
A longitudinal study of human papillomavirus carriage in human immunodeficiency virus-infected and human immunodeficiency virus-uninfected women. Am J Obstet Gynecol (1998) 1.23
Cervical abnormalities, human papillomavirus, and human immunodeficiency virus infections in women in Malawi. J Infect Dis (1996) 1.23
The natural history of human papillomavirus infection and cervical intraepithelial neoplasia among young women in the Guanacaste cohort shortly after initiation of sexual life. Sex Transm Dis (2007) 1.22
The impact of HIV status and type on the clearance of human papillomavirus infection among Senegalese women. J Infect Dis (2007) 1.20
Factors predicting the persistence of genital human papillomavirus infections and PAP smear abnormality in HIV-positive and HIV-negative women during prospective follow-up. Int J STD AIDS (2003) 1.17
Cumulative 5-year diagnoses of CIN2, CIN3 or cervical cancer after concurrent high-risk HPV and cytology testing in a primary screening setting. Int J Cancer (2005) 1.14
Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives. Cancer Epidemiol Biomarkers Prev (2007) 1.11
Repeated evaluation of human papillomavirus 16 status in cervical swabs of young women with a history of normal Papanicolaou smears. Obstet Gynecol (1992) 1.08
Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and-negative women. J Infect Dis (1996) 1.04
Persistence of an incident human papillomavirus infection and timing of cervical lesions in previously unexposed young women. Cancer Epidemiol Biomarkers Prev (2009) 1.03
Persistence and clearance of human papillomavirus infection: a prospective cohort study. Am J Obstet Gynecol (2008) 1.03
Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study. Sex Transm Dis (1996) 1.03
Determinants of persistent detection of human papillomavirus DNA in the uterine cervix. J Infect Dis (1996) 1.01
Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3,091 women. Int J Cancer (2002) 1.01
High risk human papillomavirus in women with normal cervical cytology prior to the development of abnormal cytology and colposcopy. BJOG (2000) 0.99
A population-based five-year follow-up study of cervical human papillomavirus infection. Am J Obstet Gynecol (2000) 0.98
Viral polymorphism in human papillomavirus types 33 and 35 and persistent and transient infection in the genital tract of women. J Infect Dis (2004) 0.98
Effect of diaphragm and lubricant gel provision on human papillomavirus infection among women provided with condoms: a randomized controlled trial. Obstet Gynecol (2008) 0.97
Human papillomavirus detection by the hybrid capture II assay: a reliable test to select women with normal cervical smears at risk for developing cervical lesions. Diagn Mol Pathol (2000) 0.97
Cervical human papillomavirus screening among older women. Emerg Infect Dis (2005) 0.96
Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students. Cancer Epidemiol Biomarkers Prev (2002) 0.96
HLA class II alleles associated with infection by HPV16 in cervical cancer in situ. Int J Cancer (2001) 0.96
Detection of genital human papillomavirus and associated cytological abnormalities among college women. Sex Transm Dis (1998) 0.96
A global review of age-specific and overall prevalence of cervical lesions. Int J Gynecol Cancer (2010) 0.95
Host and viral factors in relation to clearance of human papillomavirus infection: a cohort study in Taiwan. Int J Cancer (2008) 0.95
Type-specific prevalence and persistence of human papillomavirus in women in the United States who are referred for typing as a component of cervical cancer screening. Am J Obstet Gynecol (2009) 0.91
Natural history of persistent high-risk human papillomavirus infections in Korean women. Gynecol Oncol (2009) 0.89
Immunoglobulin-A and -G responses against virus-like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intra-epithelial lesions. Int J Cancer (1998) 0.89
Insulin-like growth factor axis and oncogenic human papillomavirus natural history. Cancer Epidemiol Biomarkers Prev (2008) 0.88
Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years. J Clin Virol (2009) 0.88
Dysplasia and HPV infection initially detected by DNA analysis in cytomorphologically normal cervical smears. Int J Gynaecol Obstet (1995) 0.86
Persistent HPV infection in postmenopausal age women. Int J Gynaecol Obstet (2004) 0.86
Factors predicting persistence of high-risk human papillomavirus (HPV) infections in women prospectively followed-up in three New Independent States (NIS) of the former Soviet Union. Eur J Gynaecol Oncol (2005) 0.86
Associations between serum carotenoids and tocopherols and type-specific HPV persistence: the Ludwig-McGill cohort study. Int J Cancer (2007) 0.85
Relationship between human papillomavirus type 16 in the cervix and intraepithelial neoplasia. Obstet Gynecol (1999) 0.81
Neighborhood characteristics associated with the location of food stores and food service places. Am J Prev Med (2002) 13.39
Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med (2002) 10.80
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med (2007) 10.43
Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med (2007) 9.53
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med (2010) 8.51
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 8.09
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med (2007) 7.87
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet (2006) 7.83
Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis (2008) 5.85
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology (2007) 5.77
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis (2006) 5.24
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis (2005) 5.14
Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS (2008) 4.21
Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst (2006) 4.14
Parents' health beliefs and HPV vaccination of their adolescent daughters. Soc Sci Med (2009) 4.12
Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet (2002) 3.96
Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst (2012) 3.87
Preventable drug-related hospital admissions. Ann Pharmacother (2002) 3.78
A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr (2009) 3.76
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64
Illustrating bias due to conditioning on a collider. Int J Epidemiol (2009) 3.54
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol (2012) 3.51
First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol (2010) 3.45
The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis (2009) 3.44
Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev (2005) 3.40
Longitudinal predictors of human papillomavirus vaccine initiation among adolescent girls in a high-risk geographic area. Sex Transm Dis (2011) 3.39
Evaluation of a cervicography-based program to ensure quality of visual inspection of the cervix in HIV-infected women in Johannesburg, South Africa. J Low Genit Tract Dis (2015) 3.30
The epidemiology of genital human papillomavirus infection. Vaccine (2006) 3.28
Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis (2012) 3.25
Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis (2011) 3.16
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
The ongoing tyranny of statistical significance testing in biomedical research. Eur J Epidemiol (2010) 3.10
Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Sci Transl Med (2011) 3.08
Disparities in how parents are learning about the human papillomavirus vaccine. Cancer Epidemiol Biomarkers Prev (2009) 3.07
Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. J Infect Dis (2003) 2.98
Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine (2006) 2.95
Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol (2008) 2.91
Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer (2009) 2.90
Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol (2007) 2.90
Living with p values: resurrecting a Bayesian perspective on frequentist statistics. Epidemiology (2013) 2.86
Comparison of group testing algorithms for case identification in the presence of test error. Biometrics (2007) 2.86
Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials. Biometrics (2003) 2.76
Evaluating candidate principal surrogate endpoints. Biometrics (2008) 2.74
Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial. Lancet (2012) 2.69
Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health (2008) 2.64
HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev (2008) 2.57
The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev (2003) 2.52
Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol (2007) 2.49
MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res (2010) 2.48
Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev (2006) 2.39
Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics (2003) 2.38
Process of care failures in invasive cervical cancer: systematic review and meta-analysis. Prev Med (2007) 2.35
The disparity of cervical cancer in diverse populations. Gynecol Oncol (2008) 2.27
Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. Mov Disord (2007) 2.24
Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis. AIDS (2012) 2.15
Optimizing screening for acute human immunodeficiency virus infection with pooled nucleic acid amplification tests. J Clin Microbiol (2008) 2.10
HPV vaccine acceptability in a rural Southern area. J Womens Health (Larchmt) (2008) 2.02
Delays in diagnosis and treatment among children and adolescents with cancer in Canada. Pediatr Blood Cancer (2008) 1.98
HAART and progression to high-grade anal intraepithelial neoplasia in men who have sex with men and are infected with HIV. Clin Infect Dis (2011) 1.95
Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control (2008) 1.89
Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study. J Infect Dis (2009) 1.89
Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Prev Med (2011) 1.89
Human papillomavirus vaccine initiation in an area with elevated rates of cervical cancer. J Adolesc Health (2009) 1.86
Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method. J Natl Cancer Inst (2012) 1.86
Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol (2007) 1.86
Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst (2003) 1.84
Validation of cervical cancer screening methods in HIV positive women from Johannesburg South Africa. PLoS One (2013) 1.83
HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges. Virology (2006) 1.83
Factors underlying disparities in cervical cancer incidence, screening, and treatment in the United States. Curr Probl Cancer (2007) 1.82
Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer (2003) 1.78
Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys. Cancer Epidemiol Biomarkers Prev (2006) 1.77
Potential barriers to HPV vaccine provision among medical practices in an area with high rates of cervical cancer. J Adolesc Health (2008) 1.76
Perinatal exposure to hazardous air pollutants and autism spectrum disorders at age 8. Epidemiology (2010) 1.75
Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J Infect Dis (2008) 1.72
Human papillomavirus infection among women in South and North Vietnam. Int J Cancer (2003) 1.71
Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine (2007) 1.71
Prevalence of human papillomavirus infection in women in Busan, South Korea. Int J Cancer (2003) 1.71
A time-series analysis of air pollution and preterm birth in Pennsylvania, 1997-2001. Environ Health Perspect (2005) 1.70
Management of low-grade cervical lesions in young women. CMAJ (2005) 1.69
A systematic review and meta-regression of temporal trends in adult CD4(+) cell count at presentation to HIV care, 1992-2011. Clin Infect Dis (2013) 1.67
Bounding causal effects under uncontrolled confounding using counterfactuals. Epidemiology (2005) 1.67
HPV vaccine acceptability among Kenyan women. Vaccine (2010) 1.65
Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer (2010) 1.65
Assessing the gain in diagnostic performance when combining two diagnostic tests. Stat Med (2002) 1.65
Statewide HPV vaccine initiation among adolescent females in North Carolina. Sex Transm Dis (2010) 1.64
Randomization inference for treatment effects on a binary outcome. Stat Med (2014) 1.62
Epidemiologic measures of the course and outcome of pregnancy. Epidemiol Rev (2002) 1.62
The Carolina HPV immunization attitudes and beliefs scale (CHIAS): scale development and associations with intentions to vaccinate. Sex Transm Dis (2010) 1.62
Circulating inflammation markers and prospective risk for lung cancer. J Natl Cancer Inst (2013) 1.59
Correlates of national HIV seroprevalence: an ecologic analysis of 122 developing countries. J Acquir Immune Defic Syndr (2004) 1.59
Gender difference in HIV RNA levels: a meta-analysis of published studies. J Acquir Immune Defic Syndr (2002) 1.59
IGF-I and IGFBP-3 polymorphisms in relation to circulating levels among African American and Caucasian women. Cancer Epidemiol Biomarkers Prev (2009) 1.58